Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 35 Nixon Road, Unit 1 BOLTON ON L7E 1K1 |
Tel: | 1-905-3303275 |
Website: | https://www.medexus.com/en_US |
IR: | See website |
Key People | ||
Ken D'entremont Chief Executive Officer, Director | Marcel Pascal Konrad Chief Financial Officer | Ian C. Wildgoose Brown General Counsel, Corporate Secretary |
Michael Adelman General Manager, U.S. Operations | Richard Labelle General Manager, Canadian Operations |
Business Overview |
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division's prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division's products include Rasuvo, IXINITY and Gleolan. |
Financial Overview |
For the nine months ended 31 December 2023, Medexus Pharmaceuticals Inc revenues increased 10% to $87.1M. Net loss decreased 83% to $976K. Revenues reflect Canada (Country) segment increase of 25% to $27.6M, United States (Country) segment increase of 4% to $59.5M. Lower net loss reflects Selling and administrative expenses - Ba decrease of 59% to $9.1M (expense), Foreign exchange loss (gain) increase from $1.6M (expense) to $212K (income). |
Employees: | 98 as of Mar 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $118.13M as of Dec 31, 2023 |
Annual revenue (TTM): | $158.09M as of Dec 31, 2023 |
EBITDA (TTM): | $25.45M as of Dec 31, 2023 |
Net annual income (TTM): | $8.03M as of Dec 31, 2023 |
Free cash flow (TTM): | $28.35M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $60.21M as of Dec 31, 2023 |
Shares outstanding: | 24,458,213 as of Feb 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |